Literature DB >> 9290956

BCL3 rearrangements and t(14;19) in chronic lymphocytic leukemia and other B-cell malignancies: a molecular and cytogenetic study.

T W McKeithan1, G S Takimoto, H Ohno, V S Bjorling, R Morgan, B K Hecht, I Dubé, A A Sandberg, J D Rowley.   

Abstract

The t(14;19)(q32.3;q13.1) is a recurring translocation found in the neoplastic cells of some patients with chronic lymphocytic leukemia (CLL) or other B-lymphocytic neoplasms. We previously cloned the translocation breakpoint junctions present in the leukemic cells from three such patients and identified a gene, BCL3, whose transcription is increased as a result of the translocation. In the present paper, we describe three additional patients with the t(14;19), one with lymphoma and two with CLL, and report the cloning and sequencing of the breakpoint junction in one of these patients as well as in a previously reported patient. We and others have found that the breakpoints on chromosome 14, with one exception, fall within the switch region upstream of the immunoglobulin heavy chain C alpha 1 or C alpha 2 sequences. Several of the breaks within chromosome 19 fall immediately upstream of the BCL3 gene, but several others are more than 16 kb 5' of the gene. Most patients with CLL and the t(14;19) also show trisomy 12.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9290956

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  25 in total

1.  The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition.

Authors:  S D Westerheide; M W Mayo; V Anest; J L Hanson; A S Baldwin
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 2.  Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.

Authors:  A S Baldwin
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  Human T cell leukemia virus type I tax-induced IκB-ζ modulates tax-dependent and tax-independent gene expression in T cells.

Authors:  Ryuichiro Kimura; Masachika Senba; Samuel J Cutler; Stephen J Ralph; Gutian Xiao; Naoki Mori
Journal:  Neoplasia       Date:  2013-09       Impact factor: 5.715

4.  CD8 T cells require Bcl-3 for maximal gamma interferon production upon secondary exposure to antigen.

Authors:  Paula M Chilton; Thomas C Mitchell
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

Review 5.  Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.

Authors:  Hitoshi Ohno; Momoko Nishikori; Yoshitomo Maesako; Hironori Haga
Journal:  Int J Hematol       Date:  2005-12       Impact factor: 2.490

6.  The IκB family member Bcl-3 coordinates the pulmonary defense against Klebsiella pneumoniae infection.

Authors:  Frédéric Pène; Andrea Paun; Søren Ulrik Sønder; Nimisha Rikhi; Hongshan Wang; Estefania Claudio; Ulrich Siebenlist
Journal:  J Immunol       Date:  2011-01-12       Impact factor: 5.422

7.  The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.

Authors:  Yue Zou; Mohammad M Uddin; Sveta Padmanabhan; Yan Zhu; Pengli Bu; Ales Vancura; Ivana Vancurova
Journal:  J Biol Chem       Date:  2018-08-22       Impact factor: 5.157

8.  The proto-oncogene Bcl3, induced by Tax, represses Tax-mediated transcription via p300 displacement from the human T-cell leukemia virus type 1 promoter.

Authors:  Young-Mi Kim; Neelam Sharma; Jennifer K Nyborg
Journal:  J Virol       Date:  2008-09-24       Impact factor: 5.103

9.  Bcl3 regulates pro-survival and pro-inflammatory gene expression in cutaneous T-cell lymphoma.

Authors:  Tzu-Pei Chang; Ivana Vancurova
Journal:  Biochim Biophys Acta       Date:  2014-07-30

10.  High expression of BCL3 in human myeloma cells is associated with increased proliferation and inferior prognosis.

Authors:  Anne-Tove Brenne; Unn-Merete Fagerli; John D Shaughnessy; Thea Kristin Våtsveen; Torstein Baade Rø; Hanne Hella; Fenghuang Zhan; Bart Barlogie; Anders Sundan; Magne Børset; Anders Waage
Journal:  Eur J Haematol       Date:  2009-01-13       Impact factor: 2.997

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.